FDA cautions Prolia users to be on the lookout for severe hypocalcemia
In light of the possibility of serious consequences, such as hospitalisation and death, the FDA stated that it is investigating the risk of severe hypocalcemia among dialysis patients using denosumab (Prolia). The FDA alluded to interim findings from denosumab maker Amgen’s ongoing safety trial, which revealed an elevated risk of hypocalcemia in patients with severe […]
